The Women’s Health Market Outlook to 2011

Price: $2,875.00
Published: 04/2007
Format: Hardcopy
Total pages: 224
A new report providing analysis of the current and future market for women’s health drugs across all major indications. Forecasts are given based on current marketed portfolio, drivers and resistors of growth and R&D pipelines, enabling you to predict changes in the dynamics of the global women’s health market.

Highlights
Identify high growth areas within key indications and formulate the most effective future strategy for portfolio sales growth.

Forecast sales of the major products in the women’s health area over the period 2006-11.

Evaluate market share of leading companies, such as Merck, GlaxoSmithKline and Bayer Schering Pharma.

Key findings
The leading hormonal contraceptive brand in 2005 was Schering AG’s (now Bayer Schering Pharma) Yasmin which accrued $666m in sales. Schering has recently launched a low dose version of Yasmin, called Yaz which has been approved in the additional indications of acne and PMDD and is forecast to accrue $730m in sales by 2011.

Of the newly launched products that are considered to be associated with strong potential success, GSK’s Boniva (ibandronate) indicated for the treatment of osteoporosis is forecast to accrue $1,309m by the end of the forecast period in 2011.

Although Merck held the leading position among competing companies in the WH market in 2005, its marketed franchise comprises of a lone product, Fosamax, with an indication in
osteoporosis Fosamax and its reformulated counter part Fosamax PLUS D which accrued combined sales of $2,845m in 2005.

Key indications covered:
• Osteoporosis
• Infertility
• Uterine fibroids
• Endometriosis
• Urinary incontinence
• Gynecological infections

Questions answered

* What indications are driving current growth in this therapeutic area?

* What are the current trends within the major indications such as osteoporosis, urinary incontinence and sub indications of HRT?

* How important are drug delivery and reformulation strategies to product innovation and life cycle strategies in this therapeutic area?

* Which indications within this therapeutic market are forecast to benefit the most from new product development activity in the next few years?

* Which indication is forecast to feature the strongest performance in terms of new sales from new launches by major pharmaceutical companies?

* Which companies are best positioned for success in this therapeutic area and why?

The information from and for pharmalive.com